Canada markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
14.31+0.03 (+0.21%)
At close: 04:00PM EDT
14.31 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close14.28
Open14.29
Bid14.32 x 1400
Ask14.33 x 1800
Day's Range14.25 - 14.35
52 Week Range13.17 - 17.56
Volume2,714,483
Avg. Volume2,474,761
Market Cap44.438B
Beta (5Y Monthly)1.00
PE Ratio (TTM)13.32
EPS (TTM)1.07
Earnings DateN/A
Forward Dividend & Yield0.80 (5.63%)
Ex-Dividend DateSept 29, 2021
1y Target Est18.41
  • Reuters

    Japan's Takeda forecasts rebound despite full-year profit drop

    Japan's Takeda Pharmaceutical Co said on Wednesday its 12-month operating profit slid 9.5%, although the country's largest drugmaker forecast a rebound for the current year. Chief Executive Christophe Weber said that core operating profit, which strips out impairments and other non-recurring items, would likely exceed 1 trillion yen this fiscal year, and the company's financials would become clearer now that its 2019 absorption of Shire Plc is complete. Takeda is domestically producing the COVID-19 vaccine, developed by Novavax Inc, which was approved by Japanese regulators last month.

  • Business Wire

    Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022

    OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.

  • GlobeNewswire

    CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

    Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseasesThe global market access and expansion partnership initially established in 2015 aims to provide an efficient and timely diagnosis to patientsDiagnosis remains crucial for patients, leading them towards suitable readily available t